Suchergebnisse - "Gulbrandsen, Nina"

PubPharm (46)

11

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

enthalten in: Annals of hematology | 2020

von Kaiser, M. | Beksaç, M. | Gulbrandsen, N. | +14

12

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

enthalten in: Annals of hematology | 2020

von Kaiser, M. | Beksaç, M. | Gulbrandsen, N. | +14

ErratumIn: Ann Hematol. 2021 Jan;100(1):297-302. - PMID 33106909

13

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

enthalten in: Annals of hematology | 2020

von Kaiser, M. | Beksaç, M. | Gulbrandsen, N. | +14

14

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

enthalten in: Annals of hematology | 2020

von Kaiser, M. | Beksaç, M. | Gulbrandsen, N. | +14

15

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

enthalten in: Annals of hematology | 2020

von Kaiser, M. | Beksaç, M. | Gulbrandsen, N. | +14

16

Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010 : a retrospective, population based analysis

enthalten in: BMC cancer | 2018

von Tangen, J. | Tjønnfjord, G. | Gulbrandsen, N. | +6

17

Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

enthalten in: BMC cancer | 2018

von Tangen, J. | Tjønnfjord, G. | Gulbrandsen, N. | +5

18

Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

enthalten in: BMC cancer | 2018

von Tangen, J. | Tjønnfjord, G. | Gulbrandsen, N. | +5

19

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma : a randomized study

enthalten in: European journal of haematology | 2012

von Hjorth, M. | Hjertner, �. | Knudsen, L. | +47

20

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

enthalten in: European journal of haematology | 2012

von Hjorth, M. | Hjertner, �. | Knudsen, L. | +16